Total amount: € 0,00
HOW TO ORDER
MINERVA UROLOGICA E NEFROLOGICA
A Journal on Nephrology and Urology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Minerva Urologica e Nefrologica 2002 September;54(3):189-92
Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors
Morale W. 1, Puliatti C. 1, Veroux P. 1, Veroux M. 1, Valvo C. 1, Cappello D. 1, Puliatti D. 1, Francesco L. 2
1 Centro Trapianti di Rene, I Clinica Chirurgica
2 Cattedra di Chirurgia Sostitutiva e dei Trapianti di Organo Policlinico, Università di Catania, Catania
Background. Post kidney transplantation erythrocytosis is a frequent complication in male subjects. in our experience, it occurs in approximately 20% of transplant patients recciving cyclosporine inununosuppression therapy.
Methods. Twenty-two patients with post kidney transplantation erythrocytosis were treated using ACE-inhibitors (lisinopril) at a dose of 2-5-5 mg/day for a mean period of 15 months. Owing to tbe onset of collateral effects, 27% of these patients requested the conversion of ACE into angiotensin II receptor antagonists (AII). Twenty out of 22 patients were male (90%).
Results. Treatment resulted in a 15% reduction of hematocrit values compared to basal levels, which remained stable over time. No collateral effects were recorded, either for the kidneys or in terms of hypotension.
Conclusions. ACE-inhibitors (lisinopril) or alternatively the use of angiotensin II receptor antagonists, like Iosartan at low doses, is an effective and safe treatment for patients developing post-transplantation erythrocytosis (PTE).